News &amp; Updates

Telecarers are beneficial in the monitoring of older hip fracture patients who are undergoing osteoporosis treatment, suggests a Singapore study. However, patient or family rejection and physician failure to prescribe persist as limitations of treatment.

24 Apr 2023

CPAP prevents atrial enlargementin MS patients with OSA

Treatment with continuous positive airway pressure (CPAP) for 6 months deters atrial remodeling and improves the possibility of achieving diastolic dysfunction reversibility in patients with metabolic syndrome (MS) and obstructive sleep apnoea (OSA), a study has shown.

Ventricular tachycardia may predict death in non-ischaemic cardiomyopathy patients

Ventricular tachycardia predicts all-cause death and non-sudden cardiovascular death (NSCVD) in patients with non-ischaemic cardiomyopathy, a study suggests.

24 Apr 2023

Psilocybin shows therapeutic potential for depression

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

24 Apr 2023

Urine test predicts bladder cancer risk 12 years prior to symptom onset

A simple urine test looking at genetic mutations in DNA predicts urothelial cancer – the most common type of bladder cancer – 12 years before patients develop symptoms in a recent study.

Severe COVID patients 16 times more likely to experience V-tach

Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia (V-tach) within 6 months following discharge compared with matched controls without severe infection in a Swedish case-control study presented at EHRA 2023.

24 Apr 2023

Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection

23 Apr 2023

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

23 Apr 2023

SOM3355 reduces chorea in Huntington's disease

Treatment with bevantolol hydrochloride (SOM3355) is well tolerated and results in a reduction in chorea among patients with Huntington’s disease (HD), a study has shown.

SAFO: No advantage to using two antibiotics to treat MSSA bacteraemia

22 Apr 2023 by

The use of cloxacillin alone is just as good as the combination of cloxacillin plus fosfomycin in terms of achieving treatment success among hospitalized patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia, according to the results of the open-label, phase IV-III SAFO trial presented at the ECCMID 2023.

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

22 Apr 2023 by

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.